Selinexor
Acute Myeloid Leukemia (AML)
Key Facts
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| NTLA-5001 | Intellia Therapeutics | Phase 1/2 |
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2/3 |
| SLS009 (GFH009) | SELLAS Life Sciences | Phase 1/2 |
| UCART123 | Cellectis | Phase 1 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |
| MP0533 | Molecular Partners | Phase 1/2 |
| SEL24 (MEN1703) | Selvita | Phase 1/2 |
| NEX-20 (azacitidine) | Nanexa AB | Phase 1 |
| SENTI-202 | Senti Biosciences | Phase 1 |
| motixafortide (BL-8040) | BioLineRx | Phase 2a |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |